Pluto Immunotherapeutics, Inc. — Form D
Pluto Immunotherapeutics, Inc. of LOS ANGELES, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-01-06. The offering totals $3.0M, of which $2.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-01-06
- Form: D
- Accession: 0001831908-22-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $2.8M
- Remaining: $233K
- Minimum investment: $10K
- Investors: 20
- Date of first sale: 2021-12-22
- Revenue range: Decline to Disclose
- SEC file number: 021-428232
Issuer
- Name: Pluto Immunotherapeutics, Inc.
- CIK: 0001831908
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 570 WESTWOOD PLAZA, LOS ANGELES, CA, 90095
- Phone: 818-314-1910
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Mark Cohen | Director | Bay Harbor Islands, FL |
| Gay Crooks | Director | Los Angeles, CA |
| Amelie Montel-Hagen | Director | Los Angeles, CA |
| Christopher Seet | Director | Los Angeles, CA |
| Amelie Montel-Hagen | Executive Officer | Los Angeles, CA |
| Gay Miriam Crooks | Director | Sherman Oaks, CA |
Other filings by this issuer (1)
More